Healthcare & Wellness · Industry Report
Dual Revenue, Stable Margins: Why Optometry Practices Are Recession-Resistant Consolidation Targets
Optometry in Australia combines Medicare-funded clinical services with high-margin optical retail, creating a defensive asset class ripe for scale and operational improvement.
Market Snapshot
Acquisition Benchmarks
Healthcare & Wellness · Industry Report
Dual Revenue, Stable Margins: Why Optometry Practices Are Recession-Resistant Consolidation Targets
Optometry in Australia combines Medicare-funded clinical services with high-margin optical retail, creating a defensive asset class ripe for scale and operational improvement.
Use this optometry practice report to evaluate acquisition quality faster. Understand buyer expectations, common red flags, and pricing logic before you commit to a deal.
Section 01 — Market Overview
- Key Points:*
- Australia's optometry market is mature and stable (0.2% CAGR), but fragmented - 3,435 independent and franchise operators competing with Specsavers and OPSM. Consolidation is accelerating.
- Medicare rebates cover basic eye exams (AUD 57.70 per comprehensive consultation), but optical retail dispensing (frames, lenses, contact lenses) drives profit margin - 61% gross margin on optical retail vs. 47% on contact lenses.
- Ageing population (65+ cohort rising) and childhood myopia epidemic (requiring ongoing management) create recurring, defensive demand across clinical and therapeutic services.
- Franchise models (8% Specsavers turnover vs. 10-13.5% OPSM/Luxottica) squeeze independent operator margins but provide support infrastructure and patient volume guarantees.
Market Size and Growth
Australia's optometry and optical dispensing market reached AUD 5.0 billion in 2026, with a modest five-year CAGR of 0.2% from 2020 to 2025 (IBISWorld AU, 2025). This near-flat growth trajectory masks structural stability - optometry is a defensive sector anchored by government-funded clinical services and demographic demand from an ageing population. The market contracted 0.5% in 2024, reflecting cost-of-living pressures on optical retail spending, but recovered modestly in 2025-26.
Industry Sub-Segments
| Sub-Segment | Revenue Share | Notes |
|---|---|---|
| Clinical Services (Eye Exams) | 35-40% | Medicare-funded (bulk-billed) and private billing; recurring (3-yearly under 65, annual 65+) |
| Optical Dispensing (Frames/Lenses) | 45-50% | Highest margin segment; high sensitivity to price competition (Specsavers, online retailers) |
| Contact Lenses | 8-12% | Growing therapeutic segment (myopia management); lower margins (47%) but higher patient stickiness |
| Therapeutic Optometry | 2-5% | Myopia management, low vision, atropine drops (TGA-approved 2021); premium-priced, emerging |
| Other Services | 3-5% | Dry eye management, presbyopia correction, insurance claims processing |
What's Driving Growth Right Now
- Ageing Population & Presbyopia Demand - (ABS Population Projections, 2024):* Australia's population aged 65+ is projected to grow from 16% to 20% by 2035. Presbyopic patients (age 40+) require regular lens updates and are less price-sensitive than younger cohorts. Sellers can command premium pricing for practices in retirement-dense geographic clusters.
- Childhood Myopia Epidemic - (Optometry Australia, 2025):* Myopia prevalence in Australian children aged 6-13 has risen to 28% and is accelerating due to screen time and reduced outdoor exposure. ACUVUE Abiliti contact lenses (approved by TGA in 2021) and low-dose atropine drops (TGA 2021) create recurring revenue streams and justify premium clinical fees for therapeutically endorsed optometrists.
- Therapeutic Optometry Scope Expansion - (Optometry Australia Position Statement, 2024):* Therapeutically qualified optometrists can now prescribe atropine, manage orthokeratology, and charge premium consultation fees. This expands the value pool per patient and reduces competition from budget operators. Practices with therapeutic-endorsed staff command 15-25% revenue premiums.
- Private Health Insurance Optical Cover Growth - (APRA, 2025):* Private health fund optical inclusions (traditionally weak in Australia) are expanding post-Budget 2024. Coupled with out-of-pocket rises in bulk-billed services, more patients are opting for private clinical billing. This creates pricing uplift opportunities for sellers improving their private health billing mix.
Score This Optometry Practice Deal in Minutes
Run a free BizBuyScore to benchmark this opportunity across profitability, growth, risk, and valuation so you can negotiate with confidence.
Get My Free BizBuyScore →General information only. This report contains general market information and is not financial product advice, investment advice, or a business valuation. It does not take into account your individual circumstances. Always seek independent professional advice before making any acquisition decision. Full terms →
Full Optometry Practice report available to Pro subscribers
Create a free account, then upgrade to Pro to access the complete analysis — including valuation benchmarks, M&A trends, and buyer strategy.
- ✓Valuation multiples by business size (micro to large)
- ✓Premium and discount factors with quantified multiple impact
- ✓Unit economics, margins, and break-even analysis
- ✓M&A activity, deal trends, and consolidation patterns
- ✓Buyer acquisition strategy and due diligence red flags
Evaluating a Optometry Practice?
Use the free BAS calculator to score any deal in seconds.